Dr. Barrett joined Atlas Venture in 2002, and currently serves as a partner in the life sciences group. Previously, he was a co-founder, executive vice president and chief business officer of Celera Genomics, which announced the first successful sequencing of the human genome just 2 years after its founding in 1998. Dr. Barrett helped launch Celera as a publicly traded entity in 1999. He led Celera's strategic alliances and acquisitions and participated in raising nearly $1 billion in capital for the company. Prior to Celera, Dr. Barrett held senior management positions at The Perkin-Elmer Corporation, most recently serving as vice president, corporate planning and business development. Dr. Barrett is currently vice chairman of the advisory council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University, as well as adjunct professor at the Barnett Institute. He also serves as president of the Autism Consortium, a non-profit institution. Dr. Barrett received his B.S. in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his Ph.D. in analytical chemistry from Northeastern University. He also completed Harvard Business School's Management Development Program.
Dr. Booth joined Atlas Venture in 2005, and currently serves as partner in the life sciences group, focusing on new and emerging companies developing novel biotech or pharmaceutical products, therapeutic platforms and innovative biomedical technologies. Previously, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm's private equity activities, ranging from early stage venture capital through late stage buyouts. Prior to Caxton, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector. Dr. Booth currently serves as a trustee of the New York Academy of Medicine, and is a term member of the council on foreign relations. As a British Marshall Scholar, Dr. Booth earned his Ph.D. in molecular immunology from the Oxford University's Nuffield department of medicine. He received his B.S. in biochemistry from the Pennsylvania State University.
Thomas O. Daniel, M.D. is currently Chairman, Celgene Research. Dr. Daniel was President, Research and Early Development, for Celgene Corporation over the preceding nine years. He previously served as Chief Scientific Officer and Director of AmbRx Inc. a privately held biotechnology company delivering unique protein based biotherapeutics, and as Vice President, Research at Amgen Inc. Prior to Amgen’s acquisition of Immunex, Dr. Daniel was Senior Vice President of Discovery Research at Immunex. He is currently a director of Juno Therapeutics, an innovator in the cellular therapy space, and serves as director of FerruMax and PharmAkea, two privately held biopharmaceutical companies. Dr. Daniel serves as a member of the Biomedical Science Advisory Board of Vanderbilt University Medical Center and is a member of the Therapeutic Advisory Board of aTyr Pharma, Inc. He also serves as co-chairman of the Biomedical Advisory Council of PhRMA. A nephrologist and former academic investigator, Dr. Daniel was previously the Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. He conducted research supported by the NIH and the Howard Hughes Medical Institute at UC San Francisco, earned an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital.
Ms. Heller has nearly 20 years of experience in pharmaceutical and biotechnology business development, licensing and legal affairs. During her career, Ms. Heller has led a number of strategic transactions and partnerships across a broad range of molecular modalities and in various therapeutic areas. Most recently, she was senior vice president of business development at Bristol-Myers Squibb and a Trustee of the Bristol Myers Foundation. In addition, she currently serves as a Trustee of the Dana Farber Cancer Institute. Prior to joining Bristol-Meyers Squibb, Ms. Heller was executive vice president of business development at Exelixis Pharmaceuticals, where she was successful in negotiating multiple partnerships and securing more than $500 million in guaranteed revenue. Prior to joining Exelixis, Ms. Heller was head of strategic alliances at Novartis Pharmaceuticals, where she was responsible for transactions with partners in the pharmaceutical and biotech industries, as well as academic institutions worldwide. Ms. Heller is an instructor and guest lecturer at several universities as an expert in the business of strategy setting, deal making and negotiation. Ms. Heller is a member of the California State Bar and licensed by the U.S. Patent and Trademark Office. She holds a B.S. in biology from Tulane University, an M.A. in biology from American University and a J.D. from Golden Gate University School of Law.
Dr. Hughes has more than 25 years of experience in biomedical and pharmaceutical research and development. Dr. Hughes joined Zafgen in 2008 as president, chief executive officer and a member of the company's board of directors. From 1987 to 2008, Dr. Hughes held several positions at Novartis AG (and formerly Sandoz Pharmaceuticals) including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles he oversaw many drug discovery and development projects targeting obesity, diabetes, and heart disease. As a scientist, Dr. Hughes led Novartis' efforts to discover and develop its dipeptidylpeptidase IV inhibitor vildagliptin (Galvus®/Eucreas®), a drug used for the treatment of type 2 diabetes, currently approved in 70 countries. Dr. Hughes is the author of over 40 peer-reviewed publications and is an inventor on numerous issued and pending patents related to the treatment of diabetes, cardiovascular disease, and obesity.
Dr. Hughes also serves as a director on the board of Miragen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures and Nimbus Discovery, LLC.
Dr. LaMattina is an experienced investor who has also overseen research, discovery and development processes on a global level for one of the industry's largest R&D organizations. He is currently a senior partner at PureTech Ventures and previously spent 30 years at Pfizer, where he held positions of increasing seniority and ultimately served as Senior Vice President, as well as President of Pfizer Global Research & Development. As Executive Vice President of Pfizer Global Research & Development, he was responsible for all aspects of Human Drug Discovery and Full Development worldwide. He also served on key decision-making bodies for worldwide Central Research, including the Development Planning Committee, the Global Development Research Committee, the Executive Leadership Team and the Research Leadership Team. Dr. LaMattina earned his Ph.D. in Organic Chemistry from the University of New Hampshire, and his B.S. in Chemistry from Boston College.
Dr. McDonough is President and Chief Executive Officer of Swedish Orphan Biovitrum AB (Sobi), a publicly traded international specialty healthcare company dedicated to rare diseases.
Dr. McDonough joined Sobi in August 2011 from Genzyme Corporation, where he held a variety of senior positions over a nine year period including Senior Vice President and General Manager of Genzyme’s Personalized Genetic Health division, $2.2B USD portfolio composed of four biological products, and later, President of Genzyme Europe, $1.8B USD portfolio composed of 17 products and 55 countries, 1500 employees.
Prior to joining Genzyme, Dr. McDonough was a pediatrician and internist at Massachusetts General Hospital in Boston. Dr. McDonough obtained his M.D. at Harvard Medical School, and has a B.Sc. in Biology and a B.A. in Philosophy from University of North Carolina at Chapel Hill.
Rob Perez is a biopharmaceutical operating executive with more than 25 years of experience in the industry. He is currently the founder and Managing Partner of Vineyard Sound Advisors, LLC.
Previously, he was the Chief Executive Officer of Cubist Pharmaceuticals, Inc., a public pharmaceutical development company, when the company was acquired by Merck in January 2015. He joined Cubist in August 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin® (daptomycin for injection).
He also served as Executive Vice President and Chief Operating Officer, and President prior to becoming CEO. Before joining Cubist, he served as Vice President of Biogen, Inc.’s US CNS business unit, where he was responsible for commercial leadership of an $800 million business. He joined Biogen in 1995, and was one of the architects of the commercial model that launched the company’s first commercial product, AVONEX®.
Prior to Biogen, Mr. Perez held various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez currently serves as a member of the board of directors of public companies such as AMAG Pharmaceuticals, Inc., Cidara Therapeutics, Inc., and Flex Pharma, Inc.
Mr. Perez is also a member of the board of directors of the Biomedical Science Careers Program, a member of the Board of Advisors of Citizen Schools of Massachusetts, a member of the Board of Trustees at The Dana Farber Cancer Institute, Inc., and a member of the Board of College Bound Dorchester.
Mr. Perez received a B.S. in business from California State University, Los Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
Mr. Thomas has more than 22 years of experience in high growth industries, during which he has held a variety of senior executive roles in the life sciences industry. Since November 2011 Mr. Thomas has served as Executive Vice President and Chief Operating Officer of AMAG Pharmaceuticals, Inc. He joined AMAG in August 2011 as the Executive Vice President, Chief Financial Officer.
From November 2011 to May 2012, Mr. Thomas also served as AMAG’s Interim President and Chief Executive Officer. Prior to joining AMAG he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., a public biopharmaceutical company, from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the Board of Directors of Critical Therapeutics from 2006 to 2008.
Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a biopharmaceutical company. Since 2015, he has been a member of the Board of Directors of the Massachusetts Biotechnology Council. Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.